Drug intelligence / Profile preview

CD8-targeted nanobody-lipid nanoparticle

Development stage: Unknown
Lead developer: Chengdu Weisijin Biopharmaceutical Technology
Modality: Gene Therapies, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

CD8-targeted nanobody-lipid nanoparticle (CD8-tLNP) is an innovative in vivo CAR-T cell generation platform developed by WestGene Biopharma in collaboration with West China Hospital of Sichuan University and Shanxi Provincial People's Hospital [POS0354]. The platform consists of lipid nanoparticles conjugated with human CD8-specific nanobodies (VHH) on their surface, encapsulating mRNA encoding chimeric antigen receptors (CARs), such as anti-CD19, anti-CD20, or anti-BCMA CAR mRNA. By targeting CD8+ T cells directly in vivo, the platform enables precise, transient, and repeatable programming of T-cell subsets without the need for ex vivo cell manipulation or lymphodepleting chemotherapy. It is being evaluated in Phase 1 clinical trials for B-cell malignancies (such as relapsed/refractory B-cell lymphoma) and autoimmune diseases (such as generalized myasthenia gravis in partnership with Cartesian Therapeutics).

Other names: CD19-CD8-tLNPCD-19-CD8-tLNPCD 19-CD8-tLNPCD19-CD8-tLNPsCD-19-CD8-tLNPsCD 19-CD8-tLNPsCD20-CD8-tLNPCD-20-CD8-tLNPCD 20-CD8-tLNPCD20-CD8-tLNPsCD-20-CD8-tLNPsCD 20-CD8-tLNPsCD8-targeted lipid nanoparticleCD-8-targeted lipid nanoparticleCD 8-targeted lipid nanoparticleCD8-tLNPCD-8-tLNPCD 8-tLNPCD8-tLNPsCD-8-tLNPsCD 8-tLNPs

Targets

CD8A (T-cell surface glycoprotein CD8 alpha chain)

Beyond the preview

Go deeper on CD8-targeted nanobody-lipid nanoparticle.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD8-targeted nanobody-lipid nanoparticle.